Lupin

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Stocks to Watch today, April 2, 2026: Lupin, Inox Clean Energy, Latent View Analytics, Jubilant FoodWorks, and Lemon Tree Hotels are among the top stocks to watch during today's trading session

Pharma major Lupin Ltd on Tuesday said it has received tentative approval from the US health regulator for its generic version of Sugammadex injection used for reversing the effects of muscle relaxants given during surgery. The tentative approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Sugammadex Injection of strengths 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial, Lupin said in a regulatory filing. The USFDA has tentatively approved Lupin's Sugammadex injection of the specified strengths as bioequivalent to Merck's Bridion injection, it added. It is used for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery, the company said.

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite

Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

In the past one month, Lupin has outperformed the market by soaring 6 per cent, as against 4.5 per cent decline in the BSE Sensex.

Ajit Mishra of Religare Broking has recommended buying the shares of Coal India, Hindustan Unilever, and Lupin today

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Stocks to Watch today, February 26, 2026: IRFC, RVNL, Sanofi India are among shares that will be eyed by investors today

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

Stocks to Watch today, February 25, 2026: Schaeffler India, Aditya Infotech, RVL are among few stocks that will be in focus

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Stocks to watch on February 17, 2026: Stocks like Cochin Shipyard, JSW Infrastructure, Lupin, TVS Supply Chain, and Seamec will remain in focus today

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron in the United States

Drug maker Lupin on Wednesday said its subsidiary, Lupin Atlantis Holdings SA (LAHSA), has inked a licence and supply agreement with Galenicum Health for diabetes and weight management medication. Lupin Atlantis Holdings SA (LAHSA) has entered into a partnership with Galenicum for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist. As per the agreement, Galenicum will oversee development, manufacturing, and supply, while Lupin will handle regulatory submissions, approvals, and the commercialisation and distribution of Semaglutide across 23 countries globally, including Canada, Europe, Southeast Asia, and Latin America, the Mumbai-based drug maker said in a statement. "Our partnership with Galenicum marks a strategic milestone in strengthening Lupin's Semaglutide portfolio. As diabetes continues to escalate globally and obesity emerges as a major global health priority, Semaglutide stands out as a critical therapy," said Fabrice Egros, President, Corporate ...